Elsevier

Antiviral Research

Volume 171, November 2019, 104597
Antiviral Research

The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

https://doi.org/10.1016/j.antiviral.2019.104597Get rights and content
Under a Creative Commons license
open access

Highlights

  • A ribonucleoside analog EIDD-1931 (β-D-N4-hydroxycytidine), an inhibitor of VEEV, has been characterized in mouse model.

  • EIDD-1931 is orally available with successful delivery to brain tissue and conversion to the active 5′-triphosphate form.

  • EIDD-1931 demonstrated good tolerability in 7-day dose ranging toxicology study up to 1000 mg/kg/day.

  • EIDD-1931 protects mice against lethal intranasal challenge with VEEV when dosed prophylactically or therapeutically.

Abstract

The New World alphaviruses Venezuelan, Eastern, and Western equine encephalitis viruses (VEEV, EEEV and WEEV, respectively) commonly cause a febrile disease that can progress to meningoencephalitis, resulting in significant morbidity and mortality. To address the need for a therapeutic agent for the treatment of Alphavirus infections, we identified and pursued preclinical characterization of a ribonucleoside analog EIDD-1931 (β-D-N4-hydroxycytidine, NHC), which has shown broad activity against alphaviruses in vitro and has a very high genetic barrier for development of resistance. To be truly effective as a therapeutic agent for VEEV infection a drug must penetrate the blood brain barrier and arrest virus replication in the brain. High plasma levels of EIDD-1931 are rapidly achieved in mice after oral dosing. Once in the plasma EIDD-1931 is efficiently distributed into organs, including brain, where it is rapidly converted to its active 5′-triphosphate. EIDD-1931 showed a good safety profile in mice after 7-day repeated dosing with up to 1000 mg/kg/day doses. In mouse model studies, EIDD-1931 was 90–100% effective in protecting mice against lethal intranasal infection when therapeutic treatment was started as late as 24 h post-infection, and partial protection was achieved when treatment was delayed for 48 h post-infection. These results support further preclinical development of EIDD-1931 as a potential anti-alphavirus drug.

Keywords

Alphavirus
Ribonucleoside analog
Murine model
Therapeutic treatment
CNS penetration

Abbreviations

b.i.d.
twice a day
PO
(per os) oral dosing
t1/2
terminal half-life
AUC
area under the concentration-versus-time curve
PFU
plaque forming units

Cited by (0)

1

Present addresses: JD, AstraZeneca, Frederick, MD; PRG, Recro Pharma, Inc., Gainesville, GA; DBG, Defense Threat Reduction Agency, Aberdeen Proving Ground, MD.